1. Treib J, Baron JF, Grauer MT, Strauss RG. An international view of hydroxyethyl starches. Intensive Care Med 1999; 25: 258-268. PMID:
10229159.
2. Collis RE, Collins PW, Gutteridge CN, Kaul A, Newland AC, Williams DM, et al. The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; an in vitro study. Intensive Care Med 1994; 20: 37-41. PMID:
7513003.
3. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997; 78: 974-983. PMID:
9308738.
4. Boldt J, Knothe C, Zickmann B, Andres P, Dapper F, Hempelmann G. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg 1993; 76: 1185-1190. PMID:
7684579.
5. Innerhofer P, Fries D, Margreiter J, Klingler A, Kuhbacher G, Wachter B, et al. The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 2002; 95: 858-865. PMID:
12351257.
6. Quiroga T, Perez M, Rodriguez S, Munoz B, Aranda E, Morales M, et al. Skin and mucous membrane hemorrhages: clinical assessment, study sequence and relative frequency of hereditary diseases of the hemostasis in a Chilean population. Rev Med Chil 1997; 125: 409-418. PMID:
9460281.
7. Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000; 20: 2024-2028. PMID:
10938027.
8. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22: 335-341. PMID:
11834538.
9. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-1695. PMID:
3495304.
10. Kang JG, Ahn HJ, Kim GS, Hahm TS, Lee JJ, Gwak MS, et al. The hemostatic profiles of patients with Type O and non-O blood after acute normovolemic hemodilution with 6% hydroxyethyl starch (130/0.4). Anesth Analg 2006; 103: 1543-1548. PMID:
17122237.
11. Srinivasa V, Gilbertson LI, Bhavani-Shankar K. Thromboelastography: where is it and where is it heading? Int Anesthesiol Clin 2001; 39: 35-49. PMID:
11285943.
12. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth 1992; 69: 307-313. PMID:
1389849.
13. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human Factor VIII/von Willebrand factor. J Biol Chem 1979; 254: 10754-10760. PMID:
315409.
14. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992; 267: 8723-8731. PMID:
1577715.
15. Deusch E, Gamsjager T, Kress HG, Kozek-Langenecker SA. Binding of hydroxyethyl starch molecules to the platelet surface. Anesth Analg 2003; 97: 680-683. PMID:
12933382.
16. Nielsen VG, Tan S, Brix AE, Baird MS, Parks DA. Hextend (hetastarch solution) decreases multiple organ injury and xanthine oxidase release after hepatoenteric ischemia-reperfusion in rabbits. Crit Care Med 1997; 25: 1565-1574. PMID:
9295833.
17. Treib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K. Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haematol 1996; 56: 168-172. PMID:
8598237.
18. Huraux C, Ankri AA, Eyraud D, Sevin O, Menegaux F, Coriat P, et al. Hemostatic changes in patients receiving hydroxyethyl starch: the influence of ABO blood group. Anesth Analg 2001; 92: 1396-1401. PMID:
11375811.
19. Ruttmann TG, James MF, Aronson I. In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br J Anaesth 1998; 80: 612-616. PMID:
9691864.
20. Ruttmann TG, Jamest MF, Lombard EH. Haemodilution-induced enhancement of coagulation is attenuated in vitro by restoring antithrombin III to pre-dilution concentrations. Anaesth Intensive Care 2001; 29: 489-493. PMID:
11669429.
21. Nielsen VG, Lyerly RT 3rd, Gurley WQ. The effect of dilution on plasma coagulation kinetics determined by thrombelastography is dependent on antithrombin activity and mode of activation. Anesth Analg 2004; 99: 1587-1592. PMID:
15562037.
22. Ng KF, Lam CC, Chan LC. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. Br J Anaesth 2002; 88: 475-480. PMID:
12066721.
23. Ruttmann TG, James MF, Viljoen JF. Haemodilution induces a hypercoagulable state. Br J Anaesth 1996; 76: 412-414. PMID:
8785143.
24. Bell CR, Cox DJ, Murdock PJ, Sullivan ME, Pasi KJ, Morgan RJ. Thrombelastographic evaluation of coagulation in transurethral prostatectomy. Br J Urol 1996; 78: 737-741. PMID:
8976770.
25. Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood 1992; 79: 2507-2519. PMID:
1586703.
26. Miller RD. Edited by Miller RDTransfusion Therapy. Miller's Anesthesia. 2009, 7th ed. : Philadelphia, Elsevier Churchill Livingstone. pp 1747-1768.
27. Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Effects of progressive blood loss on coagulation as measured by thrombelastography. Anesth Analg 1987; 66: 856-863. PMID:
3619091.
28. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259-264. PMID:
10691852.
29. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009; 108: 1433-1446. PMID:
19372317.
30. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products--different effects. Anesthesiology 2009; 111: 187-202. PMID:
19512862.